To evaluate the effects of nanocomposite carriers (L-FITC, AC-L-FITC, and EAC-L-FITC) on lymphocytes (CD3+CD4+ cells) and monocytes (CD11b+ cells) in PBMCs of IBD patients, we observed a subset of CD3+CD4+ T cells and CD11b+ monocytes (Additional file 1: Fig. S2a). This evidence concerns the gene ITGAM and inflammatory bowel disease.